2026 American Association for Cancer Research (AACR) Annual Meeting
Title: Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)
Presenting author: Paul Nathan
Session: Advanced Cellular and Immune-Based Therapeutics